Our Company

Our Story

About Neurim

neurim

How We Began

Established in 1991 by renowned neuroscientist Nava Zisapel and high-tech
entrepreneur Yehuda Zisapel, Neurim Pharmaceuticals’ mission is to leverage
pioneering research to discover and develop groundbreaking new medicines for
disorders related to the central nervous system (CNS), improving people’s lives
through constant innovation.

Improving Quality of Life for Patients
and their Families

neurim

Going Global

With a proven track record of drug development and commercialization, Neurim’s
first products, Circadin® and Slenyto® , are already in use in more than 40
countries across 5 continents. Constantly expanding into additional therapeutic
areas, the R&D pipeline comprises new products that address insomnia,
Alzheimer’s dementia and sleep apnea.

neurim

With the Future in Mind

Through pioneering scientific research and CNS focused drug development as
well as collaboration with public and private healthcare organizations, Neurim Pharmaceuticals is realizing its vision, addressing key unmet needs in CNS disease
management, improving the quality of life of patients and their families.

Improving People’s Lives
Through Constant Innovation

Company Leadership

Management Team

Exceptional executives and scientists, striving to drive us forward.

Prof. Nava Zisapel
CEO
Prof. Nava Zisapel
CEO
Prof. Nava Zisapel (Emeritus, Tel Aviv University), founder and CEO of Neurim Pharmaceuticals, is a renown neuroscientist with research focus on melatonin, sleep, and neurosecretion. Professor Zisapel is the principal author of over 200 papers in peer-reviewed journals and principal inventor of over 60 patents. She led the development and commercialization of the company’s first drugs and is deeply involved in discovering and developing new medicines that hold promise for patients with CNS-related conditions.
Adi Zisapel
CCO
Adi Zisapel
CCO
Since joining Neurim Pharmaceuticals in 2011, Adi Zisapel has served in several commercial roles, becoming the company’s Chief Commercial Officer in 2014. Her focus on developing the business brings impact both on Neurim's strategic partnerships worldwide and on the successful launch and performance of Neurim’s products, resulting in significant YoY growth. Adi has broadened Neurim’s global marketing, market access and sales activities, and is responsible for the development of strategic partner alliances while overseeing Neurim’s global subsidiaries. Adi holds a BSc in biotechnology engineering from the Technion (Israel Institute of Technology).
Guy Shachar
CFO
Guy Shachar
CFO
Guy Shachar joined Neurim in 2022 as VP Finance and Operations. Guy has more than 20 years of experience in senior financial management positions, and brings us deep understanding and experience in financial planning, accounting and the implementation of processes and high-end technologies to achieve measurable and sustainable results. Guy is a certified public accountant with a degree in Business Administration, a major in Accounting & Financing, and a LLM (Master of Law) degree.
Dr. Tali Nir
VP Clinical and Regulatory Affairs
Dr. Tali Nir
VP Clinical and Regulatory Affairs
Since 1997, Dr. Tali Nir has been Neurim's VP for Clinical and Regulatory Affairs, leading its global product registration and clinical development. During this time Tali has acted in various CNS fields including insomnia in adults and in the pediatric ASD population, Alzheimer’s disease, ocular hypertension, pain and sleep apnea. She has led phase 1-4 clinical studies of Neurim Pharmaceuticals’ products and pipeline, including Circadin and Slenyto, and their worldwide regulatory registration. Tali Nir is a Doctor of Veterinary Medicine with a degree from the Hebrew University of Jerusalem in Israel.
Dr. Moshe Laudon
VP Drug Discovery & Preclinical Development
Dr. Moshe Laudon
VP Drug Discovery & Preclinical Development
Dr. Moshe Laudon joined Neurim in 1992 bringing with him vast scientific and research experience. He was involved in the pharmaceutical development of Neurim's products and managed R&D functions, including drug discovery, pre-clinical, CMC and patent management. Dr. Laudon’s principal areas of research are the development of prolonged-release formulation concepts for oral drug delivery, and the investigation of novel indole derivatives. Moshe Laudon holds a Ph.D. in Neurobiochemistry from Tel-Aviv University and has published more than 80 papers and 10 patents.